CytoMed Forms Strategic Partnership for Cancer Treatments

Partnership Between CytoMed and SunAct for Cancer Trials

CytoMed Therapeutics Limited (NASDAQ: GDTC), a biopharmaceutical company based in Singapore, proudly announces a significant collaboration with SunAct Cancer Institute in India. This partnership marks the initiation of a Phase 2 clinical trial focused on a groundbreaking cancer treatment. The trial will primarily evaluate the safety and efficacy of CytoMed's allogeneic gamma delta T cells in combating solid tumors, which could potentially revolutionize treatment approaches.

Innovative Approaches to Cancer Therapy

The aim of this collaboration is to accelerate the utilization and development of cutting-edge cell-based immunotherapy. This approach promises to deliver more affordable treatment alternatives to cancer patients in India, supporting broader access to necessary therapies. By leveraging SunAct's extensive expertise and state-of-the-art facilities, together with CytoMed's proprietary technology and manufacturing strengths, both organizations aspire to push the boundaries of cancer treatment.

Expert Insights on the Clinical Trial

Dr. Vijay Patil, a notable oncologist affiliated with SunAct, voiced his optimism regarding the potential contributions this study could bring to the global fight against cancer. CytoMed's Chairman, Peter Choo, also expressed enthusiasm, emphasizing the synergy with SunAct’s commitment to effective, affordable cancer therapeutics. This strong alignment in visions lays a solid foundation for mutual success in their endeavors.

Long-term Collaboration Details

The agreement between the two entities is designed for a term spanning five years, during which they will jointly sponsor the clinical trial. CytoMed is set to provide essential scientific and technical support while also producing the investigational gamma delta T cells. This collaborative spirit is crucial as both companies navigate the complexities of clinical research.

Cancer Immunotherapy Advancements in India

This venture occurs amid a broader push in India for advancements in cancer immunotherapy, driven by supportive regulation and research incentives. The Central Drugs Standard Control Organization (CDSCO) of India plays a crucial role in overseeing international clinical trials, ensuring that new therapies meet stringent safety and efficacy standards.

CytoMed's Background and Recent Achievements

Founded in 2018 and spun off from Singapore's Agency for Science, Technology and Research (ASTAR), CytoMed specializes in developing innovative immunotherapies aimed at treating cancer. Concurrently, SunAct Cancer Institute has earned a reputation as a leader in cancer research and treatment, particularly noted for its pioneering CAR T-cell therapy efforts.

Recent Developments and Future Prospects

Recently, CytoMed Therapeutics Limited has also announced the commencement of a Phase I clinical trial for a novel CAR-T cell therapy, referred to as the ANGELICA Trial. This trial, in collaboration with the National University Hospital of Singapore, uses a first-in-class method employing allogeneic chimeric antigen receptor T cells derived from healthy donors. This approach has the potential to enhance efficacy and reduce the costs associated with CAR-T cell therapies significantly.

Investments in Cord Blood Banking

Additionally, CytoMed has made strides in expanding its capabilities by acquiring a licensed cord blood bank in Malaysia through its subsidiary, LongevityBank Pte Ltd. This investment aims to utilize cord blood-derived biologics for research on aging diseases and regenerative medicine, reflecting the company's commitment to innovative healthcare solutions.

Acquisition of New Assets

In line with its strategic growth, CytoMed recently purchased assets from Cellsafe International Sdn Bhd, a Malaysian cord blood bank, for approximately $490,000. This acquisition not only includes a cord blood banking license and cryopreservation equipment but also encompasses over 12,000 cord blood units along with two real estate properties. Such investments aim to broaden the utility of cord blood for treating various conditions, including solid cancers.

Advancements in Stem Cell Technology

Furthermore, CytoMed has been awarded a Malaysian patent for its innovation in utilizing induced pluripotent stem cell (iPSC)-derived hybrid gamma delta Natural Killer T (?? NKT) cells technology. This advancement could potentially target a diverse range of cancers without necessitating genetic editing, which is a significant leap in cancer treatment methodologies. The company's management has received approval to invest in this promising venture, aligning with its overarching goal to create affordable, readily available immune cell therapies for life-threatening diseases, especially cancers.

Frequently Asked Questions

What is the purpose of the clinical trial between CytoMed and SunAct?

The trial aims to evaluate the safety and efficacy of allogeneic gamma delta T cells as a treatment for solid tumors.

How long will the collaboration between CytoMed and SunAct last?

The collaboration is set for a term of five years, during which joint sponsorship of the clinical trial will occur.

What recent advancements have been made by CytoMed?

CytoMed has initiated the ANGELICA Trial and acquired a cord blood bank in Malaysia for research related to regenerative medicine.

Why is the agreement significant for cancer treatment in India?

This partnership aims to provide more affordable, effective treatment options for cancer patients in India, leveraging both companies' strengths.

What technology has CytoMed been patented for?

CytoMed received a patent for iPSC-derived hybrid gamma delta NKT cells technology, which targets various cancers without genetic editing.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.